Evidence map›Paper›PMID 36773467›Full record

ArticlePsychiatry research2023

Discovery of early schizophrenia through neuroimaging.

Adrienne C Lahti

Open access · greenAbstract read
In one paragraph

Article in Psychiatry research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Adrienne C LahtiDepartment of Psychiatry and Behavioral Neurobiology, The University of Alabama at Birmingham, Birmingham, AL, United States. Electronic address: alahti@uabmc.edu.
University of Alabama at Birmingham · US

Funding

Trajectories of treatment response as window into the heterogeneity of psychosis: a longitudinal multimodal imaging study in medication-naieve first episode psychosis patientsR01MH113800 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LAHTI, ADRIENNE C · 2018 to 2022
$3.9M
Glutamate, brain connectivity and duration of untreated psychosisR01MH102951 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LAHTI, ADRIENNE C · 2014 to 2018
$2.9M
Treatment response in schizophrenia: bridging imaging and postmortem studiesR01MH081014 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LAHTI, ADRIENNE C · 2009 to 2013
$1.8M
BLOOD FLOW CHANGES AND ANTIPSYCHOTIC DRUG ACTIONR01MH057971 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI LAHTI, ADRIENNE C · 1999 to 2002
$837k
NIMH NIH HHS R01 MH057971NIMH NIH HHS R01 MH081014NIMH NIH HHS R01 MH102951NIMH NIH HHS R01 MH113800
6 · The paper itself

Abstract

In order to understand the pathophysiology of schizophrenia we carried out a number of brain imaging studies in both medicated and unmedicated patients. In addition, to help unravel the pathophysiological mechanisms without the confound of prior exposure to antipsychotic medication or chronicity, we enrolled a large group of antipsychotic medication-naïve first episode psychosis patients at first treatment contact, and performed longitudinal multimodal neuroimaging studies over several months. In unmedicated patients we found both functional and structural connectivity alterations. Similarly, in medication-naïve patients we replicated many of our prior findings, suggesting that functional and structural connectivity alterations are core pathological features of the illness. We found that a longer duration of untreated psychosis, i.e. the time between first symptom onset and initial treatment contact, was associated with greater structural and functional connectivity abnormalities, which in turn was associated with worse subsequent clinical response to treatment. These results underscore the critical importance of early identification and treatment in patients with psychosis spectrum disorders.

Indexed as

Antipsychotic AgentsPsychotic DisordersSchizophreniaHumansMagnetic Resonance ImagingNeuroimagingAntipsychotic AgentsAntipsychotic drugBrain imagingSchizophrenia

Identifiers

PMID36773467
PMCPMC12266044
OpenAlexW4310136168

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.